12 novel pyrazolylbenzo[d]imidazoles were designed and synthesized.
Their inhibition potential was evaluated against hCA I, II, IX and XII.
Compounds having sulfonamide moiety were better inhibitors with poor selectivity.
Selectivity against tumor isoforms hCA IX abd XII enhanced on removing sulfonamide.
Inhibition results were promising as compared to antitumor drug acetazolamide.